SCLX_OUT_1 [2025-04-02 12:44:48 -0400] 3009 Bytes | 832 tokens | Cum: 832 tkns (10.40% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Scilex (SCLX) hit my radar screen, up to 0.3049 from a prev close of 0.2375 Do you think its got more juice or is it lacking potential? It's 12:44:48 PM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Scilex (SCLX)
IPO: IPO date unknown
Shares Outstanding: 243,310,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here's the first list of news for Scilex:

C1 - Mar-26-25 08:24PM - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
C2 - Mar-10-25 09:00AM - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
C3 - Jan-31-25 09:00AM - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
C4 - Jan-22-25 08:00AM - Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication
C5 - Jan-21-25 11:49AM - Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
C6 - Jan-21-25 11:49AM 09:46AM - Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
C7 - Jan-21-25 11:49AM 09:00AM - Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
C8 - Jan-21-25 11:49AM 07:00AM - Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Scilex (SCLX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SCLX_OUT_3 [2025-04-02 12:44:52 -0400] 1107 Bytes | 332 tokens | Cum: 1166 tkns (14.57% of 8k)
==========================================================================

Showing C4 (chunk 1 of 10): C4:
**Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication**
Date: Jan-22-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/01/22/3013439/0/en/Scilex-Holding-Company-Announces-that-the-U-S-FDA-Has-Acknowledged-the-Submission-of-Our-Supplemental-New-Drug-Application-for-ELYXYB-in-Acute-Pain-Indication.html

January 22, 2025 08:00 ET| Source:Scilex Holding CompanyScilex Holding Company

PALO ALTO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_5 [2025-04-02 12:44:53 -0400] 956 Bytes | 286 tokens | Cum: 1534 tkns (19.18% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T10:33:32Z - North American Morning Briefing: Stocks Fall With -2-...
A2 - 2025-03-27T07:04:52Z - Scilex (NASDAQ:SCLX) Stock Price Up 1.8% - Here's What Happened...
A3 - 2025-03-27T00:45:40Z - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federa...
A4 - 2025-03-27T00:24:29Z - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federa...
A5 - 2025-03-27T00:34:44Z - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federa...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCLX_OUT_7 [2025-04-02 12:45:02 -0400] 1098 Bytes | 312 tokens | Cum: 1848 tkns (23.10% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**North American Morning Briefing: Stocks Fall With -2-**Date: 2025-03-31Source: {'uri': 'morningstar.com', 'dataType': 'news', 'title': 'Morningstar'}URL: https://www.morningstar.com/news/dow-jones/202503312692/north-american-morning-briefing-stocks-fall-with-2On Friday, Putin called for "interim governance" in Ukraine under the auspices of the United Nations, which would essentially push out Ukrainian President Volodymyr Zelensky.

Richards Packaging Income Fund: Trustee Gerry Glynn Dies

Senvest Capital 2024 EPS C$105.06

Vision Marine Technologies (VMAR) Halted due to pending news

04:30/JPN: Feb Preliminary Report on Petroleum Statistics

08:30/UK: Feb Money and Credit - Lending to Individuals, Lending to Businesses, Broad Money and Credit

13:45/US: Mar Chicago Business Barometer - ISM-Chicago Business Survey - Chicago PMI

All times in GMT. Powered by Kantar Media and Dow Jone

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_9 [2025-04-02 12:45:03 -0400] 1098 Bytes | 341 tokens | Cum: 2375 tkns (29.69% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): s.

Expected Earnings for Monday

Abaxx Technologies Inc (ABXX.GR) is expected to report for 4Q.

Accord Financial Corp (ACD.T) is expected to report for 4Q.

American Hotel Income Properties REIT LP (HOT.UN.T) is expected to report for 4Q.

Babcock & Wilcox Enterprises Inc (BW) is expected to report $-0.01 for 4Q.

Brainstorm Cell Therapeutics Inc (BCLI) is expected to report for 4Q.

California First Leasing Corp (CFNB) is expected to report for 1Q.

Carisma Therapeutics Inc (CARM) is expected to report $-0.12 for 4Q.

Celcuity Inc (CELC) is expected to report $-0.71 for 4Q.

Dawson Geophysical Co (DWSN) is expected to report for 4Q.

Houston American Energy Corp (HUSA) is expected to report for 4Q.

INNOVATE Corp (VATE) is expected to report for 4Q.

Kartoon Studios Inc (TOON) is expected to report for 4Q.

Koil Energy Solutions Inc (KLNG) is expected to report for 4Q.

Lazydays Holdi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_11 [2025-04-02 12:45:04 -0400] 1475 Bytes | 402 tokens | Cum: 2779 tkns (34.74% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-27T00:24:00Z - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
B2 - 2025-01-16T20:38:00Z - Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
B3 - 2024-11-22T11:00:00Z - Scilex Holding Company Announces Receipt of Notice from Nasdaq
B4 - 2024-10-29T10:00:00Z - Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
B5 - 2024-10-28T10:00:00Z - Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
B6 - 2024-10-11T20:30:00Z - Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCLX_OUT_13 [2025-04-02 12:45:07 -0400] 957 Bytes | 263 tokens | Cum: 3044 tkns (38.05% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/27/3050229/0/en/Scilex-Holding-Company-Has-Appealed-Lower-Court-Decision-to-the-U-S-Court-of-Appeals-for-the-Federal-Circuit-in-Washington-DC-and-Will-Continue-to-Vigorously-Pursue-its-Infringemen.htmlScilex Holding Company has appealed a lower court decision that found its ZTlido patents were not infringed by Aveva. Scilex remains confident in the strength of its intellectual property and will continue to pursue the infringement case on appeal.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_15 [2025-04-02 12:45:08 -0400] 1115 Bytes | 279 tokens | Cum: 3403 tkns (42.54% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read together with the CONS financial statements and related notes thereto ...

S2 - 2025-03-10 8-K Item 7.01.Regulation FD Disclosure.

On March 10, 2025, Scilex Holding Company (the Company) issued a press release announcing that its Board of Directors (the Board) has approved a change to the previously announced record date of January 28, 2025 for its previously announced d...

S3 - 2025-03-03 8-K Item1.01. Entry into a Material Definitive Agrmt.

Background

As previously announced, on January 2, 2025, Scilex Holding Company (the Company ) entered into a Deferral and Consent under Tranche B Senior Secured Convertible Note (collectively, the Deferral and Consent Lett...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCLX_OUT_17 [2025-04-02 12:45:09 -0400] 1098 Bytes | 229 tokens | Cum: 3634 tkns (45.42% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Annual Report on Form 10-K, including those set forth in the sections of this Annual Report on Form 10-K titled Risk Factors and Cautionary Note Regarding Forward-Looking Statements.

O

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_19 [2025-04-02 12:45:10 -0400] 1098 Bytes | 252 tokens | Cum: 3888 tkns (48.60% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): verview

We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients lives. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018, in-licensed two commercial products in 2022 and 2023, and are developing our late-stage pipeline. Our commercial product, ZTlido (lidocaine topical system) 1.8% (ZTlido), is a prescription lidocaine topical product approved by the U.S. Food and Drug A

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCLX_OUT_21 [2025-04-02 12:45:23 -0400] 5931 Bytes | 1617 tokens | Cum: 5507 tkns (68.84% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-----------------------+
| Volume: 1,881,154 | Perf Month: 4.22% | Option/Short: Yes / Yes | Sales Y/Y TTM: 21.07% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 1.36M | Perf Quarter: -25.58% | Short Float: 3.36% | ROE: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 2.84 | Index: - | Short Ratio: 4.45 | ROI: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 54.70 | Market Cap: 76.26M | Short Interest: 6.05M | Sales Surprise: 0.00% |
+-------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.04 | Shs Outstand: 183.24M | Beta: 1.05 | EPS Surprise: 25.70% |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 8.59% | Shs Float: 180.22M | Sales Q/Q: 10.68% | P/E: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -5.60% | Inst Own: 20.29% | Sales past 5Y: 16.35% | Earnings: Feb 26 |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -63.96% | Insider Own: 25.93% | Employees: 115 | |
+-------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 23.48% | Insider Trans: 0.23% | Debt/Eq: - | |
+-------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Scilex Holding Co (SCLX) by SCLX Stock Acquisition JV LLC (Unknown Title) on 2025-01-21
- Common Stock: 3250000 shares at $N/A (D) Footnote: Transferred pursuant to the terms of an Amendment to Senior Secured Promissory Note (the "Amendment Letter") the Issuer and the Reporting Person entered into with Oramed Pharmaceuticals Inc. ("Oramed") for the extension of the maturity date of that certain senior secured promissory note previously issued by the Issuer to Oramed on September 21, 2023. Under the terms of the Amendment Letter and in consideration for such extension and to limit certain noteholders' rights to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Amendment Letter)), the Reporting Person transferred to Oramed an aggregate of 3,250,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person.

Inside Trans: Scilex Holding Co (SCLX) by SCLX Stock Acquisition JV LLC (Unknown Title) on 2025-01-16
- Common Stock: 779371 shares at $N/A (D) Footnote: Transferred in connection with a First Amendment to License and Commercialization Agreement (the "License Amendment") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the "Transfer Agreement"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 55152000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -87747000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.3122
Average Volume: 1427717.74
30-Day High: 0.35
30-Day Low: 0.2375

[Detailed Financials: Q3 2024]
- Total Assets: $100,430,000.0
- Total Liabilities: $311,747,000.0
- Total Equity: $-211,317,000.0
- Current Assets: $39,855,000.0
- Current Liabilities: $281,537,000.0

[Income Statement: Q3 2024]
- Revenue: $14,436,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.03

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-1,563,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $104,544,000.0
- Total Liabilities: $319,236,000.0
- Total Equity: $-214,692,000.0
- Current Assets: $50,418,000.0
- Current Liabilities: $255,451,000.0

[Income Statement: Q2 2024]
- Revenue: $16,370,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $6,881,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SCLX_OUT_23 [2025-04-02 12:45:25 -0400] 676 Bytes | 167 tokens | Cum: 5928 tkns (74.10% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SCLX_IN_25 [2025-04-02 12:45:25 -0400] 126 Bytes | 29 tokens | Cum: 5985 tkns (74.81% of 8k)
==========================================================================

====================================
[2025-04-02 12:45:25] # Analysis Completed
Elapsed Time: 37.21 seconds